Loading clinical trials...
Loading clinical trials...
FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1
Conditions
Interventions
Bemarituzumab
Placebo
+1 more
Locations
189
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
The Oncology Institute of Tuscon
Tucson, Arizona, United States
Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc
Greenbrae, California, United States
Sutter Medical Group
Sacramento, California, United States
UCLA Medical Centre - Santa Monica Hematology and Oncology
Santa Monica, California, United States
Innovative Clinical Research Institute (ICRI)
Whittier, California, United States
Start Date
September 14, 2018
Primary Completion Date
September 23, 2020
Completion Date
May 13, 2022
Last Updated
February 28, 2024
NCT04704661
NCT04550494
NCT05489211
NCT05702229
NCT04674267
NCT07217704
Lead Sponsor
Five Prime Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions